Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note published on Wednesday morning,Zacks reports. The firm issued a strong-buy rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently weighed in on SUPN. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research note on Wednesday. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Finally, Piper Sandler initiated coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $47.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.50.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $28.21 on Wednesday. The stock has a market capitalization of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84. Supernus Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $42.81. The stock has a fifty day moving average of $41.74 and a 200-day moving average of $47.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.14). The firm had revenue of $208.60 million for the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same period last year, the company earned ($0.80) EPS. Equities research analysts forecast that Supernus Pharmaceuticals will post 3.66 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The business also recently disclosed a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be issued a $8.13 dividend.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Equitec Proprietary Markets LLC bought a new position in shares of Supernus Pharmaceuticals during the third quarter worth $143,000. Pictet Asset Management Holding SA grew its holdings in shares of Supernus Pharmaceuticals by 0.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock valued at $19,116,000 after buying an additional 2,437 shares during the period. CenterBook Partners LP bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $876,000. Heritage Family Offices LLP bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $128,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Supernus Pharmaceuticals News Roundup

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.